Mohamed ElRefai
@ElRefai_MD
Followers
196
Following
365
Media
52
Statuses
391
Cardiologist https://t.co/K03Z8LEPUs https://t.co/jEC3GKc35Z
United Kingdom
Joined September 2019
Can we use deep-learning methods to guide patient selection for S-ICD therapy? . Can artificial intelligence tools guide S-ICD programming to reduce oversensing and inappropriate shocks?. Do we need to revisit S-ICD screening criteria?. @JICE_EP
link.springer.com
Journal of Interventional Cardiac Electrophysiology - A major predictor of eligibility of subcutaneous implantable cardiac defibrillators (S-ICD) is the T:R ratio. The eligibility cut-off of the...
1
2
6
Iconic.
0
0
0
“Always be kind around the hospitals. You’ll find people dealing with fear, grief, stress—rushing in with worry, waiting with hope, praying for news. Oh—and yes, there are also the patients”.
0
0
0
RT @colossal: SOUND ON. You’re hearing the first howl of a dire wolf in over 10,000 years. Meet Romulus and Remus—the world’s first de-exti….
0
27K
0
RT @drraviele: 📌 In👫anticipated to require frequent ventricular pacing.👉 Biventricular pacing is not superior to RV pacing.#EPeeps #CardioT….
0
13
0
Interesting. Is there a case to consider implanting pacemakers on the opposite side for patients who underwent previous LIMA grafting? 🧐.
Focal Aneurysm Formation in a Coronary Bypass Graft Following Permanent Pacemaker Implantation.
0
0
0
Scar burden, not the ejection fraction.
Late-gadolinium enhancement predicts appropriate device therapies in non-ischemic recipients of primary prevention implantable cardioverter-defibrillators #OpenAccess.
0
0
0
Heart Failure with Preserved Ejection Fraction | New England Journal of Medicine
nejm.org
Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors.
0
0
0
Substitute one pillar for another? 🤔🧐. Finerenone: Will It Be a Game-changer? | CFR Journal
cfrjournal.com
Heart failure (HF) is a major contributor to hospitalisations and accounts for 7% of cardiovascular-related deaths, with patients who have chronic kidney disease and type 2 diabetes at
0
0
0
And youngest ever.
The emotional moment that 18-year-old Gukesh Dommaraju became the 18th world chess champion 🥲🏆
0
0
0
Happy to share our review on Device Therapy in Cardiac Sarcoidosis. Challenges and future prospectives.@DrMenexi .
0
0
3
SGLT2 inhibitors between the zeal of the clinical studies and the challenges of the day-to-day practice. How 2 overcome inertia when it comes to #GDMT in #Heartfailure #dapagliflozin .@MAb_Card @pmhaydock @dralicezheng
0
0
2
RT @dr_benoy_n_shah: Deep dive on #EARLYTAVR from ##TCT2024. Lots already said & discussed. It takes time to read the paper, read the suppl….
0
162
0
RT @dr_benoy_n_shah: Tomorrow - Oct 28th - we learn the results of 3 landmark randomised studies in patients with aortic stenosis (AS). Res….
0
54
0
RT @BBCBreaking: Groundbreaking Alzheimer's drug donanemab rejected for use in NHS in England after watchdog says it does not justify cost….
bbc.co.uk
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.
0
189
0
RT @GianluSava: Enjoying the #ESC_HFA Clinical trial course in HF in Naples. Great programme, international audience, amazing faculty! @Wil….
0
13
0
RT @Dominik_Linz: #ESCCongress #ESCGuidelines. The 2024 ESC Guidelines for the management of #AFib. Check out here the .- Full manuscript.-….
0
20
0
Thank you @JICE_EP for publishing our work led by @Lin_T_Toon on the safety of day case leadless pacemaker implants @Uhs_Cardiac @UHSFT.
🚨New #FreeRead Article in.@JICE_EP. Is Day-Case Surgical Procedure Safe for MICRA Leadless Pacemaker Implantation?. 🧐📖 by Lin-Thiri Toon, @ElRefai_MD, @MAb_Card, Roopa Patil, John Paisey, @DrArthurYue & Paul Roberts . #EPeeps
0
0
2